Genea Biocells provides the world’s first commercially available media system to differentiate human pluripotent stem cells into functional skeletal muscle. It is based on our most efficient and robust technology platform <link to ‘Technology Platform’>’Skeletal muscle differentiation’>. The process does not require any cell sorting or overexpression of myogenic transcription factors (Caron et al. 2016. Stem Cells Translational Medicine 5: 1145–61). We, our collaborators and our customers successfully differentiated over 50 human embryonic and induced pluripotent stem cell lines. The third generation of our media suite is now available and offers further improved yields, robustness and enhanced myotube formation.